Trastuzumab products (intravenous) — Clinical coverage and authorization criteria
Customize your policy alerts
Sign up for all quartz policy alerts
Know when quartz releases new policies or updates existing guidance.
Monitor payer policy activity
Clinical coverage and authorization guidance for trastuzumab and its biosimilars for HER2-positive malignancies for Quartz members; includes FDA-approved and supported off-label uses and dosing summaries.
No material clinical or coverage changes in this revision.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.